SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation

RZLT

Related stories